Celsion to Hold Annual Meeting

Shareholders May Participate by Telephone or Webcast
COLUMBIA, Md.--(Business Wire)--
Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development company
that is leveraging its heat sensitive liposomal technology platform to
encapsulate and deliver high concentrations of proven chemotherapeutics, will
hold its Annual Meeting of Stockholders on Friday, May 15, 2009 at 10:00 AM ET
at Baltimore Marriott Waterfront, 700 Aliceanna Street, Baltimore, MD 21202.

Shareholders who are unable to attend the meeting are invited to participate by
telephone; interested parties should dial (877) 604-2080 (domestic) and (706)
902-1383 (international), Conference ID: 98821076 to register ten minutes before
the meeting is scheduled to begin. The meeting can also be accessed via webcast
at the Celsion Corporation's website at www.celsion.com.

The proceedings will be archived for audio replay from Friday, May 15, 2008 at
12:00 PM ET until Friday, May 22. The replay can be accessed at (800) 642-1687
(domestic) and (706) 645-9291 (international). The webcast will be archived on
the Company's website, www.celsion.com, for 90 days.

About Celsion

Celsion is dedicated to the development and commercialization of innovative
oncology drugs including tumor-targeting treatments using focused heat energy in
combination with heat-activated drug delivery systems. Celsion has licensed
ThermoDox to Yakult-Honsha for the Japanese market and has a partnership
agreement with Phillips Medical to jointly develop its heat activated liposomal
technology in combination with high intensity focused ultrasound to treat
difficult cancers. Celsion has research, license, or commercialization
agreements with leading institutions such as the National Institutes of Health,
Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and
the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release
are made pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without limitation,
unforeseen changes in the course of research and development activities and in
clinical trials by others; possible acquisitions of other technologies, assets
or businesses; possible actions by customers, suppliers, competitors, regulatory
authorities; and other risks detailed from time to time in the Company's
periodic reports filed with the Securities and Exchange Commission.

Celsion Corporation
Sean Moran, 410-290-5390
Senior Vice President and Chief Financial Officer
smoran@celsion.com
or
The Trout Group
Marcy Nanus, 646-378-2927
mnanus@troutgroup.com

Copyright Business Wire 2009